Sai Life Sciences Ltd
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
- Market Cap ₹ 23,103 Cr.
- Current Price ₹ 1,091
- High / Low ₹ 1,139 / 700
- Stock P/E 66.5
- Book Value ₹ 118
- Dividend Yield 0.00 %
- ROCE 19.2 %
- ROE 14.9 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 39.7% CAGR over last 5 years
Cons
- Stock is trading at 9.21 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.6% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 695 | 725 | 751 | 841 | 1,157 | 1,419 | 1,642 | 2,153 | |
| 520 | 556 | 587 | 716 | 990 | 1,131 | 1,248 | 1,553 | |
| Operating Profit | 175 | 170 | 164 | 125 | 167 | 288 | 394 | 600 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 28% |
| 6 | 18 | 27 | 28 | 27 | 29 | 36 | 41 | |
| Interest | 24 | 21 | 32 | 51 | 74 | 81 | 72 | 33 |
| Depreciation | 44 | 52 | 72 | 80 | 88 | 107 | 126 | 152 |
| Profit before tax | 112 | 114 | 88 | 22 | 33 | 129 | 232 | 456 |
| Tax % | 35% | 30% | 25% | 30% | 26% | 26% | 25% | 25% |
| 73 | 80 | 65 | 16 | 24 | 95 | 173 | 341 | |
| EPS in Rs | 8.32 | 16.12 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 444% | 279% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 23% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 40% |
| 3 Years: | 142% |
| TTM: | 99% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 45% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 13% |
| Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 18 | 18 | 18 | 18 | 21 | 21 |
| Reserves | 700 | 778 | 850 | 873 | 895 | 993 | 2,147 | 2,487 |
| 250 | 304 | 637 | 752 | 869 | 868 | 287 | 223 | |
| 246 | 291 | 312 | 464 | 349 | 361 | 682 | 872 | |
| Total Liabilities | 1,212 | 1,389 | 1,816 | 2,106 | 2,131 | 2,240 | 3,137 | 3,603 |
| 373 | 617 | 659 | 701 | 923 | 1,074 | 1,378 | 1,705 | |
| CWIP | 116 | 79 | 236 | 345 | 151 | 107 | 124 | 270 |
| Investments | 0 | 22 | 63 | 64 | 80 | 80 | 114 | 163 |
| 722 | 671 | 858 | 996 | 977 | 979 | 1,521 | 1,465 | |
| Total Assets | 1,212 | 1,389 | 1,816 | 2,106 | 2,131 | 2,240 | 3,137 | 3,603 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 127 | 109 | -26 | 88 | 221 | 251 | 330 | ||
| -158 | -259 | -279 | -95 | -111 | -190 | -565 | ||
| 268 | -1 | 304 | 81 | -190 | -85 | 314 | ||
| Net Cash Flow | 237 | -152 | -2 | 75 | -80 | -24 | 80 | |
| Free Cash Flow | -30 | -139 | -267 | -109 | 156 | 72 | -33 | |
| CFO/OP | 89% | 75% | -6% | 77% | 135% | 92% | 89% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 98 | 103 | 87 | 67 | 78 | 63 |
| Inventory Days | 86 | 77 | 124 | 185 | 123 | 73 | 96 | 98 |
| Days Payable | 208 | 247 | 244 | 284 | 176 | 114 | 270 | 200 |
| Cash Conversion Cycle | 0 | -34 | -21 | 4 | 35 | 25 | -96 | -40 |
| Working Capital Days | 55 | 32 | 60 | 49 | 42 | 20 | 69 | 76 |
| ROCE % | 13% | 9% | 4% | 6% | 11% | 14% | 19% |
Insights
In beta| Mar 2009 | Mar 2011 | Mar 2013 | Mar 2017 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Installed Reactor Capacity KL |
|
||||||||
| Active Customers (Innovators) Number |
|||||||||
| Capacity Utilization (Average) % |
|||||||||
| Commercial Molecules (CDMO) Number |
|||||||||
| Molecules in Phase III / Pre-registration Number |
|||||||||
| Headcount - Scientists Number |
|||||||||
| Product Development Pipeline (Early-Phase) Number |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16h - Newspaper publication for the Audited Financial Results for the quarter and year ended 31 March 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Sai Life Sciences uploaded Q4/FY26 audited results earnings call recording on 15 May 2026.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
1d - Allotment of 92,000 Equity Shares under ESOP Schemes of the Company.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
1d - CRISIL monitoring report for quarter ended 31 March 2026 shows IPO proceeds fully utilized, no deviations.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
1d - Investor Presentation for the quarter and year ended 31 March 2026.
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Feb 2025TranscriptPPT REC
Business Profile[1]
Sai Life Sciences is an integrated CRDMO (Contract Research, Development and Manufacturing Organization) delivering end-to-end services across the pharmaceutical lifecycle from early drug discovery to commercial manufacturing.